These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 16343978)

  • 21. Alterations in CIITA constitute a common mechanism accounting for downregulation of MHC class II expression in diffuse large B-cell lymphoma (DLBCL).
    Cycon KA; Rimsza LM; Murphy SP
    Exp Hematol; 2009 Feb; 37(2):184-194. PubMed ID: 19081173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CIITA transformation rescues the apoptotic function of MHC class II in melanoma cells.
    Le E; Zhang H; Blanck G
    Anticancer Res; 2005; 25(6B):3889-92. PubMed ID: 16312044
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of PU.1 in MHC class II expression through transcriptional regulation of class II transactivator pI in dendritic cells.
    Kitamura N; Yokoyama H; Yashiro T; Nakano N; Nishiyama M; Kanada S; Fukai T; Hara M; Ikeda S; Ogawa H; Okumura K; Nishiyama C
    J Allergy Clin Immunol; 2012 Mar; 129(3):814-824.e6. PubMed ID: 22112519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHC genes in ocular melanoma cells.
    Radosevich M; Song Z; Gorga JC; Ksander B; Ono SJ
    Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):3185-95. PubMed ID: 15326139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Co-occupancy of the interferon regulatory element of the class II transactivator (CIITA) type IV promoter by interferon regulatory factors 1 and 2.
    Xi H; Eason DD; Ghosh D; Dovhey S; Wright KL; Blanck G
    Oncogene; 1999 Oct; 18(43):5889-903. PubMed ID: 10557076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.
    Thompson JA; Dissanayake SK; Ksander BR; Knutson KL; Disis ML; Ostrand-Rosenberg S
    Cancer Res; 2006 Jan; 66(2):1147-54. PubMed ID: 16424052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Revisiting the specificity of the MHC class II transactivator CIITA in vivo.
    Otten LA; Leibundgut-Landmann S; Huarte J; Kos-Braun IC; Lavanchy C; Barras E; Borisch B; Steimle V; Acha-Orbea H; Reith W
    Eur J Immunol; 2006 Jun; 36(6):1548-58. PubMed ID: 16703565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Downregulation of CIITA function by protein kinase a (PKA)-mediated phosphorylation: mechanism of prostaglandin E, cyclic AMP, and PKA inhibition of class II major histocompatibility complex expression in monocytic lines.
    Li G; Harton JA; Zhu X; Ting JP
    Mol Cell Biol; 2001 Jul; 21(14):4626-35. PubMed ID: 11416140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathologic expression of MHC class II is driven by mitogen-activated protein kinases.
    Martins I; Deshayes F; Baton F; Forget A; Ciechomska I; Sylla K; Aoudjit F; Charron D; Al-Daccak R; Alcaide-Loridan C
    Eur J Immunol; 2007 Mar; 37(3):788-97. PubMed ID: 17304627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The MHC class II transactivator (CIITA) mRNA stability is critical for the HLA class II gene expression in myelomonocytic cells.
    De Lerma Barbaro A; Procopio FA; Mortara L; Tosi G; Accolla RS
    Eur J Immunol; 2005 Feb; 35(2):603-11. PubMed ID: 15627980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autoimmunity and inflammation are independent of class II transactivator type PIV-dependent class II major histocompatibility complex expression in peripheral tissues during collagen-induced arthritis.
    Waldburger JM; Palmer G; Seemayer C; Lamacchia C; Finckh A; Christofilopoulos P; Baeten D; Reith W; Gabay C
    Arthritis Rheum; 2011 Nov; 63(11):3354-63. PubMed ID: 21739421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Introduction of exogenous class II trans-activator in MHC class II-deficient ABI fibroblasts results in incomplete rescue of MHC class II antigen expression.
    Peijnenburg A; Gobin SJ; van Eggermond MC; Godthelp BC; van Graafeiland N; van den Elsen PJ
    J Immunol; 1997 Sep; 159(6):2720-7. PubMed ID: 9300692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination gene therapy with CD86 and the MHC class II transactivator in the control of lung tumor growth.
    Martin BK; Frelinger JG; Ting JP
    J Immunol; 1999 Jun; 162(11):6663-70. PubMed ID: 10352284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CIITA versus IFN-gamma induced MHC class II expression in head and neck cancer cells.
    Meissner M; Whiteside TL; Kaufmann R; Seliger B
    Arch Dermatol Res; 2009 Feb; 301(2):189-93. PubMed ID: 19104823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Challenge with mammary tumor cells expressing MHC class II and CD80 prevents the development of spontaneously arising tumors in MMTV-neu transgenic mice.
    Jabrane-Ferrat N; Campbell MJ; Esserman LJ; Peterlin BM
    Cancer Gene Ther; 2006 Nov; 13(11):1002-10. PubMed ID: 16841083
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prolonged MHC class II expression and CIITA transcription in human keratinocytes.
    Takagi A; Nishiyama C; Kanada S; Niwa Y; Fukuyama K; Ikeda S; Okumura K; Ogawa H
    Biochem Biophys Res Commun; 2006 Aug; 347(2):388-93. PubMed ID: 16836979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells.
    Meazza R; Comes A; Orengo AM; Ferrini S; Accolla RS
    Eur J Immunol; 2003 May; 33(5):1183-92. PubMed ID: 12731043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T cell expression of CIITA represses Th1 immunity.
    Park WS; Bae Y; Chung DH; Choi YL; Kim BK; Sung YC; Choi EY; Park SH; Jung KC
    Int Immunol; 2004 Oct; 16(10):1355-64. PubMed ID: 15351782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correction of defective expression in MHC class II deficiency (bare lymphocyte syndrome) cells by retroviral transduction of CIITA.
    Bradley MB; Fernandez JM; Ungers G; Diaz-Barrientos T; Steimle V; Mach B; O'Reilly R; Lee JS
    J Immunol; 1997 Aug; 159(3):1086-95. PubMed ID: 9233601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of alloresponse by a human trophoblast non-coding RNA suppressing class II transactivator promoter III and major histocompatibility class II expression in murine B-lymphocytes.
    Geirsson A; Bothwell AL; Hammond GL
    J Heart Lung Transplant; 2004 Sep; 23(9):1077-81. PubMed ID: 15454174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.